Dendrite Equips Solvay Pharmaceuticals With First U.S. Deployment of ForcePharma.

MORRISTOWN, NJ--(BUSINESS WIRE)--Sept. 29, 1999--

Dendrite International, Inc. (Nasdaq/NMS: DRTE) today announced the successful rollout of ForcePharma for Solvay Pharmaceuticals, Inc., a research-based pharmaceutical company based in Marietta, Ga.. The contract includes Dendrite software and support services that cover nearly 1100 Solvay Pharmaceuticals sales representatives, managers and contracted sales force personnel.

Designed exclusively for the pharmaceutical marketplace, ForcePharma enhances sales force effectiveness (SFE) and productivity by providing easy access to actionable information in a clear and user-friendly format. Dendrite was able to complete its first U.S. deployment of ForcePharma to Solvay Pharmaceuticals in an efficient time frame of just three months.

Chairman and CEO of Dendrite International John Bailye said of the deployment, "I'm very pleased by the completion of this rollout and the positive feedback we have received from Solvay Pharmaceuticals. We firmly believe that our ForcePharma product is ahead of the SFE curve and that its technology unfailingly delivers real benefits without inhibiting the user in any way."

"Being the first U.S. deployment of ForcePharma was not without risks," said Tom Hall, Senior Manager of Information Services at Solvay Pharmaceuticals, "but the Dendrite team was committed to a successful, rapid deployment to support our ongoing business initiatives."

"The Dendrite ForcePharma solution was selected by Solvay Pharmaceuticals to allow the integration of other best-of-breed software products on the field laptops. ForcePharma supports our objective of delivering actionable data to the territory level, as well as timely summarized and detailed data at the management level," continued Hall. "The ForcePharma implementation allows Solvay Pharmaceuticals to leverage state-of-the-art technology for all of our field users."

ABOUT SOLVAY PHARMACEUTICALS

Solvay Pharmaceuticals, Inc. of Marietta, Georgia, is a research-based pharmaceuticals company, active in the therapeutic areas of cardiology, women's health, mental health and gastroenterology. It is a member of the worldwide Solvay Group of chemical and pharmaceutical companies, headquartered in Brussels, Belgium.

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1100 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the application of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.